Replies to post #197612 on Biotech Values

[semi_infinite]

CHRS has Humira and Enbrel FoBs in the pipeline in addition to Neulasta FoB. What fraction of their value derives from Neulasta FoB expectations?

http://investors.coherus.com/Mobile.view?c=253655&d=4&v=100